+

WO1998010078A3 - Cloning of full-length human pex cdna - Google Patents

Cloning of full-length human pex cdna Download PDF

Info

Publication number
WO1998010078A3
WO1998010078A3 PCT/CA1997/000617 CA9700617W WO9810078A3 WO 1998010078 A3 WO1998010078 A3 WO 1998010078A3 CA 9700617 W CA9700617 W CA 9700617W WO 9810078 A3 WO9810078 A3 WO 9810078A3
Authority
WO
WIPO (PCT)
Prior art keywords
pex
renal failure
chronic renal
hyperphosphatemia
cloning
Prior art date
Application number
PCT/CA1997/000617
Other languages
French (fr)
Other versions
WO1998010078A2 (en
Inventor
Andrew C Karaplis
David Goltzman
Janet E Henderson
Mark L Lipman
Dibyendu Panda
Yingnian Shen
Original Assignee
Andrew C Karaplis
David Goltzman
Janet E Henderson
Mark L Lipman
Dibyendu Panda
Yingnian Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrew C Karaplis, David Goltzman, Janet E Henderson, Mark L Lipman, Dibyendu Panda, Yingnian Shen filed Critical Andrew C Karaplis
Priority to AU41073/97A priority Critical patent/AU4107397A/en
Priority to CA002264955A priority patent/CA2264955A1/en
Publication of WO1998010078A2 publication Critical patent/WO1998010078A2/en
Publication of WO1998010078A3 publication Critical patent/WO1998010078A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to the cloning of full-length human PEX cDNA isolated from tumors causing oncogenous hypophosphatemia osteomalacia, uses of PEX active site for the design of drugs to inhibit protein activity in cases of hyperphosphatemia or chronic renal failure, uses of the PEX active site as a target for the treatment of hyperphosphatemia or chronic renal failure and uses in the diagnosis of hyperphosphatemia or chronic renal failure, use of PEX for the design of drugs to inhibit protein activity in cases of hyperphosphatemia or chronic renal failure, use of PEX as a target for the treatment of hyperphosphatemia, chronic renal failure, hypophosphatemia or idiopathic hypercalcuria, and use of PEX in the diagnosis of hyperphosphatemic states, chronic renal failure, hypophosphatemic states or idiopathic hypercalcuria.
PCT/CA1997/000617 1996-09-05 1997-09-04 CLONING OF FULL-LENGTH HUMAN PEX cDNA WO1998010078A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU41073/97A AU4107397A (en) 1996-09-05 1997-09-04 Cloning of full-length human pex cdna
CA002264955A CA2264955A1 (en) 1996-09-05 1997-09-04 Cloning of full-length human pex cdna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2545496P 1996-09-05 1996-09-05
US60/025,454 1996-09-05

Publications (2)

Publication Number Publication Date
WO1998010078A2 WO1998010078A2 (en) 1998-03-12
WO1998010078A3 true WO1998010078A3 (en) 1998-07-09

Family

ID=21826161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000617 WO1998010078A2 (en) 1996-09-05 1997-09-04 CLONING OF FULL-LENGTH HUMAN PEX cDNA

Country Status (3)

Country Link
AU (1) AU4107397A (en)
CA (1) CA2264955A1 (en)
WO (1) WO1998010078A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
AU2004222823B2 (en) * 1999-02-24 2006-11-30 Enobia Pharma Inc. Composition, Methods and Reagents for the Synthesis of a Soluble Form of Human PHEX
EP1293568A4 (en) * 2000-06-21 2005-10-26 Takeda Pharmaceutical NEW PROTEIN AND ITS DNA
ATE341631T1 (en) * 2000-08-23 2006-10-15 Enobia Pharma Inc METHOD AND COMPOSITION FOR PROMOTING OSTEOGENesis
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
CA2431308C (en) 2000-12-07 2010-04-13 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A gene ( PEX ) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium.", NATURE GENETICS, vol. 11, no. 2, October 1995 (1995-10-01), pages 130 - 136, XP002056683 *
DATABASE EMBL 21 January 1997 (1997-01-21), LIPMAN M.L. ET AL.: "Human metalloendopeptidase analog (PEX) mRNA, complete sequence.", XP002056687 *
DU L. ET AL.: "cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.", GENOMICS, vol. 36, no. 1, 15 August 1996 (1996-08-15), pages 22 - 28, XP002056685 *
NELSON A. E. ET AL.: "The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 132, no. 1-2, 19 September 1997 (1997-09-19), pages 1 - 5, XP002056686 *
ROWE P. S.: "Molecular biology of hypophosphatemics rickets and oncogenic osteomalacia.", HUMAN GENETICS, vol. 94, no. 5, November 1994 (1994-11-01), pages 457 - 467, XP002056684 *

Also Published As

Publication number Publication date
AU4107397A (en) 1998-03-26
WO1998010078A2 (en) 1998-03-12
CA2264955A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
BR9915134A (en) Co-therapy and combination therapy for the treatment of cardiovascular disorders in an individual, and composition
WO1999017755A3 (en) Medicaments
NZ510509A (en) Compounds that specifically inhibit factor VIIa activity used to inhibit blood clotting and inflammatory response
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2001036365A3 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
WO2004029091A3 (en) FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
BR9710362A (en) Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
IL147442A (en) Composition comprising a pro364 or pro175 polypeptide in admixture with a pharmaceutically acceptable carrier and cardiovascular, endothelial or angiogenic agent, pharmaceutical compositions comprising them and their use for preparing medicaments
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
FR2777183B1 (en) USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME
CA2406057A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
WO1998010078A3 (en) Cloning of full-length human pex cdna
PL338415A1 (en) Application of physiologically compatible vanadium compounds, salts and complexes
CA2311128A1 (en) Composition with azelaic acid
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2094200A (en) Cosmetic or medical preparation for topical use
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
BR0006088A (en) Protein derivatives c
EP0967276A3 (en) Anti-tumor agent comprising salmosin
EP1652924A3 (en) Polypeptide, cDNA encoding the same and use thereof
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264955

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2264955

Country of ref document: CA

NENP Non-entry into the national phase

Ref document number: 1998512071

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 09260045

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载